alipogene tiparvovec

Trade name: glybera

Gene therapyexperimental

Alipogene tiparvovec, sold under the brand name Glybera, is a gene therapy treatment designed to reverse lipoprotein lipase deficiency (LPLD), a rare recessive disorder, due to mutations in LPL, which can cause severe pancreatitis. It was recommended for approval by the European Medicines Agency in July 2012, and approved by the European Commission in November of the same year. It was the first marketing authorisation for a gene therapy treatment in either the European Union or the United States. — Wikipedia

Clinical trial activity

3 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
2
Phase 4
0

Earliest trial started Aug 1, 2007 (NCT01109498)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • alipogene tiparvovec
  • alipogene tiparvovec
  • alipogene tiparvovec
  • alipogene tiparvovec
  • glybera

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02904772Phase 2Oct 1, 2016Chiesi, UniQure N.V., University of Sherbrooke
NCT00891306Phase 2/Phase 3 (Phase 3)Feb 1, 2009Amsterdam Molecular Therapeutics, The Clinical Trial Company
NCT01109498Phase 2/Phase 3 (Phase 3)Aug 1, 2007Amsterdam Molecular Therapeutics, International Antiviral Therapy Evaluation Center (IATEC)
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Amsterdam Molecular TherapeuticsFor profit2212007
ChiesiFor profit1012016
International Antiviral Therapy Evaluation Center (IATEC)Academic/Hospital1012007
The Clinical Trial CompanyFor profit1012009
UniQure N.V.For profit1112016
University of SherbrookeAcademic/Hospital1012016
6 organizations
Page 1 / 1